Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Feb 5;99(3):1491-6.
doi: 10.1073/pnas.022630299. Epub 2002 Jan 15.

Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation

Affiliations

Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation

Giovanna Angelini et al. Proc Natl Acad Sci U S A. .

Abstract

T lymphocytes are defective in cystine uptake and thus require exogenous thiols for activation and function. Here we show that monocyte-derived human dendritic cells (DCs) release cysteine in the extracellular space. Cysteine generation is increased by lipopolysaccharide and tumor necrosis factor alpha, and by contact with T cells specifically recognizing soluble or alloantigens. These stimuli also induce thioredoxin (TRX) accumulation in DCs. However, only the contact with antigen-specific T cells triggers TRX secretion by the antigen-presenting cells. Fewer extracellular thiols are recovered after DC-T cell interactions when cystine uptake or TRX activity are inhibited. In addition, glutamate (Glu) and anti-TRX-inactivating antibodies inhibit antigen-dependent T lymphocyte proliferation. These findings indicate that, during antigen presentation, DCs uptake cystine and release cysteine and TRX, thus providing a reducing microenvironment that facilitates immune response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Thiol release by DCs is induced by T cells. Eight-day DCs (7 × 104), untreated or treated for the last 24 h with LPS, were incubated 6 h alone (DCs; DCs-LPS) or with alloreactive T cells from a parallel primary 7-day MLR (DCs + alloT; DCs-LPS + alloT) or with T cells from a 7-day MLR between two uTs (DCs + uT) at a DC/T cell ratio of 1:10. As a control, DCs were fixed for 10 min with 1% glutaraldehyde before coculture with alloreactive T cells (GA-DCs + alloT). In a separate experiment (filled columns), DCs were cultured alone (DCs) or loaded overnight with tetox (DCs + tetox) and then incubated for 6 h with autologous tetox-specific T cells at the same DC/T cell ratio (DCs + tetox + tetoxT). At the end of the incubation, thiols present in the supernatants were evaluated by DTNB colorimetric assay. As a control, thiol release by the same number of alloreactive (alloT) or tetox-specific T cells (tetoxT) is shown. One representative experiment of six is shown ± SD.
Figure 2
Figure 2
Cys is the major small thiol released by DCs. The supernatants from 5 × 105 nonstimulated (DCs), LPS-stimulated DCs (DCs + LPS), or DCs incubated with alloreactive T cells at a DC/T cell ratio of 1:10 (DCs + alloT), were analyzed for the presence of Cys, Cys2, or GSH by HPLC. Open columns show the amounts present in fresh medium.
Figure 3
Figure 3
Regulation of TRX synthesis and secretion in human DCs by LPS, TNF-α, or antigen-specific T cells. (A) Aliquots of the lysates (cyt, Upper) and supernatants (sec, Lower) from untreated DCs (lane 1), or DCs treated for the last 24 h with LPS (lane 2) or TNF-α (lane 3), cultured for 6 h alone (lanes 1–3) or with alloreactive (lane 4, alloT), or nonspecific T cells (lane 5, uT) or CD40L-transfected cells (lane 6, CD40L), were resolved under reducing conditions and transferred to nitrocellulose filters. Filters were decorated with polyclonal anti-TRX antibodies. Cell lysates and supernatants from the same number of alloreactive T cells (lane 7) and CD40L-transfected cells (lane 8) cultured alone are included as controls. (B) Lysates (cyt, Upper) and supernatants (sec, Lower) of 8-day DCs cultured alone for 6 h (lane 1), or loaded with tetox and incubated for 6 h alone (lane 2, tetox), with autologous anti-tetox T cells (lane 3, tetox + tetoxT) or with nonspecific activated T cells (lane 4, tetox + uT) were analyzed by Western blotting with anti-TRX as in A.
Figure 4
Figure 4
Glutamate and antibodies inactivating TRX (9G9) inhibit the accumulation of extracellular thiols. LPS-stimulated DCs (7 × 104; DCs + LPS) were incubated alone, and the same number of immature DCs were incubated with alloreactive T cells (DCs + alloT). Incubations were performed 6 h in the presence of 2 mM Glu, 50 μM BCNU, 100 μM DCNB, 5 μg/ml of 2B1 or 9G9 mAb, or 2 mM Glu plus 5 μg/ml of 9G9 mAb. Thiols present in supernatants at the end of the culture period were determined by DTNB assay. Results are expressed as the percent of thiol release relative to untreated 6-h cultures of LPS-DCs (open columns) or DCs-alloreactive T cells (gray columns). One representative experiment of three is shown ± SD.
Figure 5
Figure 5
Glutamate and 9G9 inhibit T cell proliferation induced by antigen-presenting DCs. Eight-day DCs (5 × 104) were incubated with alloreactive T cells from a parallel primary 7-day MLR (DCs + alloT) or loaded with tetox and incubated with autologous tetox-specific T cells (DCs + tetoxT), at a DC/T cell ratio of 1:4, in the presence or absence of 2 mM Glu or 5 μg/ml of 9G9 or 2B1 mAb, or 5 μg/ml of 9G9 and 50 μM Cys (this condition was tested on DC + alloT cocultures only), as indicated. [3H]Thymidine incorporation was evaluated at day 3. Results are expressed as the percent of [3H]thymidine incorporation relative to control cocultures of DC-alloreactive T cells (filled columns, 55,826 ± 6,895 cpm) or of DCs-tetox-specific T cells (open columns, 66,318 ± 3,153 cpm). No significant differences in [3H]thymidine incorporation were observed when LPS-treated DCs were used (not shown). Mean of three different experiments ± SD.

Comment in

Similar articles

Cited by

References

    1. Meister A. J Biol Chem. 1994;269:9397–9400. - PubMed
    1. Staal F J, Anderson M T, Staal G E, Herzenberg L A, Gitler C, Herzenberg L A. Proc Natl Acad Sci USA. 1994;91:3619–3622. - PMC - PubMed
    1. Hutter D E, Till B G, Greene J J. Exp Cell Res. 1997;232:435–438. - PubMed
    1. Messina J P, Lawrence D A. J Immunol. 1989;143:1974–1981. - PubMed
    1. Suthanthiran M, Anderson M E, Sharma V K, Meister A. Proc Natl Acad Sci USA. 1990;87:3343–3347. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

-